Non-Hodgkin Lymphoma News

Non-Hodgkin Lymphoma - Videos

STOP! You must read this information before you decide about your cancer treatment. Over 350 non-toxic natural and alternative treatments that have helped thousands of people beat their cancer. Over 2,000 testimonials! Success rates for surgery, chemo and radiation revealed! Free information on financial and other help available. Download this set of 4 e-Books and Reports NOW. It could save your life.

The set of e-books and reports at www.naturalcancertreatments.com gives you EVERYTHING you need to know about natural and alternative treatments for cancer.

Non-Hodgkin’s Lymphoma - News

Non-Hodgkin’s Lymphoma News

Non-Hodgkins Lymphoma - Google News
©2010 Google
Google News

FDA Postpones Panel Meeting To Review Cell Therapeutics' Drug Due To Extreme ... - RTT News

TopNews United States

FDA Postpones Panel Meeting To Review Cell Therapeutics' Drug Due To Extreme ... RTT News The company is seeking approval of Pixantrone for the treatment of relapsed and refractory non-Hodgkin's lymphoma. Shares of Cell Therapeutics were hammered ... Cell Therapeutics drug draws US FDA staff concernsReuters Cell Therapeutics Shares Fall as FDA Says Lymphoma Drug Has “Substantial” Side ...Xconomy FDA Announces Inadequate Clinical Data on Proposed Cancer Drug PixantroneTopNews New Zealand TechFlash (blog) -TopNews United States -MarketWatch all 81 news articles »

Small Caps Drop to Fresh 2010 Lows Wall Street Journal ... the Food and Drug Administration said that there was limited clinical evidence on the Seattle company's proposed drug to treat non-Hodgkin's lymphoma. ... and more »

US HOT STOCKS: Electronic Arts, Harman Active In Late Trading Wall Street Journal ... was limited clinical evidence involving a proposed Cell Therapeutics Inc. (CTIC, $0.64, -$0.42, -39.62%) drug that would treat non-Hodgkin's lymphoma. ... and more »

High-calorie diet increases cancer risk: SQU study Zawya Non-Hodgkin's lymphoma (NHL) is a type of cancer affecting the white blood cells. It is a neoplastic disorder of the lymphatic system characterised by ...

Family, friends gather to remember Vincenzo Graziano Torrington Register Citizen Granziano died from non-Hodgkin's lymphoma in 2005 at age 27. Every year since his sudden death, family and friends have gathered to honor ...

US HOT STOCKS: Electronic Arts, Harman Active In Late Trading Wall Street Journal ... was limited clinical evidence involving a proposed Cell Therapeutics Inc. (CTIC, $0.64, -$0.42, -39.62%) drug that would treat non-Hodgkin's lymphoma. ...

CenturyTel, DR Horton, Imergent, Lennar: US Equity Movers BusinessWeek The company may not have enough data to prove its experimental drug Pixuvri works against aggressive non-Hodgkin's lymphoma, US regulators said, ... and more »

Blog - US Markets World Market Media (blog) Spectrum, with its already FDA approved Zavala, for non Hodgkin's lymphoma and Fusible for osteosarcoma cancer is ready to introduce its third phase 2 drug ...

Bortezomib effective for some indolent non-Hodgkin's lymphomas Curetoday.com (press release) NEW YORK (Reuters Health) - The proteasome inhibitor bortezomib (Velcade) is effective in patients with follicular lymphoma and other indolent non-Hodgkin's ...

Filipino cancer victim searches for marrow donor Vallejo Times-Herald She allowed Tony Corallo to refocus his attention from the pain of his non-Hodgkin's lymphoma and onto his smiling daughter. At 38, Tony Corallo still ... and more »

The Leukemia & Lymphoma Society's LymphomaCAST
Podcast for those living with Hodgkin and non-Hodgkin lymphoma. Sponsored by The Leukemia & Lymphoma Society

NHL: Treatment Advances from ASH
December 17, 2009 NHL: Treatment Advances from the American Society of Hematology (ASH) Annual Meeting This program featured Jonathan W. Friedberg, MD, MMSc, Associate Professor of Medicine, Chief, Hematology/Oncology Division, Director, Hematological Malignancies Clinical Research, Wilmot Cancer Center, University of Rochester, Rochester, NY.
Treating Uncommon Lymphomas
October 14, 2009 Treating Uncommon Lymphomas: Dialogue With an Expert on T-Cell, MALT, and Waldenström Macroglobulinemia This program featured Richard R. Furman, MD, Assistant Professor, Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Weill Medical College of Cornell University, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by grants from Allos Therapeutics, Inc. and Eisai Inc.
Emerging Therapies in NHL: Understanding Your Options
September 22, 2009 - Part 2 (Q&A) Emerging Therapies in NHL: Understanding Your Options This program featured Andrew D. Zelenetz, MD, PhD, Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by grants from Genentech BioOncology and biogen idec.
Emerging Therapies in NHL: Understanding Your Options
September 22, 2009 - Part 1 (Presentation) Emerging Therapies in NHL: Understanding Your Options This program featured Andrew D. Zelenetz, MD, PhD, Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by grants from Genentech BioOncology and biogen idec.
NHL: Understanding Diagnosis and Making Treatment Decisions
NHL: Understanding Diagnosis and Making Treatment Decisions June 24, 2009 - Part 2 (Q&A) This program featured Steven H. Bernstein, MD, Professor of Medicine, Co-Director, Lymphoma Biology Program, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an unrestricted educational grant from Genentech BioOncology and biogen idec. This program was in collaboration with Abrale, our partner organization. http://www.leukemia-lymphoma.org/all_page?item_id=492628
NHL: Understanding Diagnosis and Making Treatment Decisions
NHL: Understanding Diagnosis and Making Treatment Decisions June 24, 2009 - Part 1 (Presentation) This program featured Steven H. Bernstein, MD, Professor of Medicine, Co-Director, Lymphoma Biology Program, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an unrestricted educational grant from Genentech BioOncology and biogen idec. This program was in collaboration with Abrale, our partner organization. http://www.leukemia-lymphoma.org/all_page?item_id=492628
Update on Mantle Cell Lymphoma - Part 2
Update on Mantle Cell Lymphoma - Part 2 (Q&A) June 18, 2009 This program featured Owen A. O'Connor, MD, PhD, Associate Professor of Medicine, Director, Lymphoid Development and Malignancy Program, Chief, Lymphoma Service, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, Columbia University, New York, NY. This program was supported by Celgene and Millennium, The Takeda Oncology Company.
Update on Mantle Cell Lymphoma - Part 1
Update on Mantle Cell Lymphoma - Part 1 (Presentation) June 18, 2009 This program featured Owen A. O'Connor, MD, PhD, Associate Professor of Medicine, Director, Lymphoid Development and Malignancy Program, Chief, Lymphoma Service, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, Columbia University, New York, NY. This program was supported by Celgene and Millennium, The Takeda Oncology Company.
Emerging Therapies in Leukemia, Lymphoma & Myeloma
Emerging Therapies in Leukemia, Lymphoma & Myeloma June 16, 2009 This program featured Gail J. Roboz, MD, Associate Professor of Medicine, Director, Leukemia Program, Weill Medical College of Cornell University/New York-Presbyterian Hospital, New York, NY and John P. Leonard, MD, Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Professor of Medicine, Weill Medical College of Cornell University/New York-Presbyterian Hospital, Clinical Director, New York - Cornell Center for Lymphoma and Myeloma, New York, NY and Robert Z. Orlowski, MD, PhD, Director, Myeloma Section, Associate Professor, Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX. This program was supported in part by Celgene.
News on NHL from the ASH Annual Meeting - Part 2
12/18/2008 - Part 2 (Q&A) News on NHL from the American Society of Hematology (ASH) Annual Meeting This program featured Bruce D. Cheson, MD, FACP, Professor of Medicine, Head of Hematology, Director, Hematology Research, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an educational grant from Genentech BioOncology and Biogen Idec.
News on NHL from the ASH Annual Meeting - Part 1
12/18/2008 - Part 1 (Presentation) News on NHL from the American Society of Hematology (ASH) Annual Meeting This program featured Bruce D. Cheson, MD, FACP, Professor of Medicine, Head of Hematology, Director, Hematology Research, Lombardi Cancer Center, Georgetown University Hospital, Washington, DC. This program was sponsored by The Leukemia & Lymphoma Society and was supported by an educational grant from Genentech BioOncology and Biogen Idec.
Childhood Leukemia and Lymphoma: An Update
Childhood Leukemia and Lymphoma: An Update on Current and Emerging Therapies This program featured Sima Jeha, M.D., Director, Leukemia/Lymphoma Developmental Therapeutics, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. This program was sponsored by The Leukemia & Lymphoma Society and was supported by a grant from The Jeff Gordon Foundation.
NHL: Current Treatments and Emerging Therapies - Part 2
NHL: Current Treatments and Emerging Therapies September 8, 2008 - Part 2 (Q&A) This program featured Andrew D. Zelenetz, M.D., Ph.D., Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society, and was supported by an unrestricted educational grant from Genentech BioOncology and Biogen Idec. For related information go to http://www.leukemia-lymphoma.org/all_page?item_id=492628
NHL: Current Treatments and Emerging Therapies - Part 1
NHL: Current Treatments and Emerging Therapies September 8, 2008 - Part 1 (Presentation) This program featured Andrew D. Zelenetz, M.D., Ph.D., Chief, Lymphoma Service, Division of Hematology/Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. This program was sponsored by The Leukemia & Lymphoma Society, and was supported by an unrestricted educational grant from Genentech BioOncology and Biogen Idec. For related information go to http://www.leukemia-lymphoma.org/all_page?item_id=492628
Childhood Cancer Survivorship: The Family's Journey Forward
5/29/2008 This program featured Nancy F. Cincotta, M.S.W., L.C.S.W., A.C.S.W., B.C.D., psychosocial director, Camp Sunshine, Casco, ME. This program was sponsored by The Leukemia & Lymphoma Society.
Progress in NHL Treatment, Part 2
5/20/2008, Part 2 This program on non-Hodgkin lymphoma (NHL) featured John W. Sweetenham, M.D., professor of medicine, director of clinical research, Taussig Cancer Institute, Cleveland Clinic, Ohio. This program was sponsored by The Leukemia & Lymphoma Society. In collaboration with Abrale.
Progress in NHL Treatment, Part 1
5/20/2008, Part 1 This program on non-Hodgkin lymphoma (NHL) featured John W. Sweetenham, M.D., professor of medicine, director of clinical research, Taussig Cancer Institute, Cleveland Clinic, Ohio. This program was sponsored by The Leukemia & Lymphoma Society. In collaboration with Abrale.
Progress in Mantle Cell Lymphoma: Update from the Experts 2
4/30/2008 - Part 2 This program featured John P. Leonard, MD, The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY and Brad S. Kahl, MD, Associate Professor of Medicine, Director, Lymphoma Service, University of Wisconsin School of Medicine and Public Health, Madison, WI. This program was sponsored by The Leukemia & Lymphoma Society and supported by Celgene and Millennium Pharmaceuticals.
Progress in Mantle Cell Lymphoma: Update from the Experts 1
4/30/2008 - Part 1 This program featured John P. Leonard, MD, The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY and Brad S. Kahl, MD, Associate Professor of Medicine, Director, Lymphoma Service, University of Wisconsin School of Medicine and Public Health, Madison, WI. This program was sponsored by The Leukemia & Lymphoma Society and supported by Celgene and Millennium Pharmaceuticals.
Stem Cell Transplantation: Current Trends/Future Directions
2/21/2008 This program featured Armand Keating, MD, FRCP(C), Professor of Medicine, Director, Division of Hematology, Epstein Chair in Cell Therapy and Transplantation at the University of Toronto. Director, Cell Therapy Program at Princess Margaret Hospital/Ontario Cancer Institute in Toronto, Ontario, Canada. This program was sponsored by The Leukemia and Lymphoma Society. Click here for the direct link to the audio: http://lls.hipcast.com/deluge/c940160b-5502-04f4-cb52-949b96782aaf.mp3
Sexuality and Intimacy After Cancer
3/11/2008 This program featured Sage Bolte, MSW, LCSW, OSW-C, Oncology Counselor, Breast Cancer Program, Life with Cancer® Inova Cancer Services in Fairfax, Virginia. This program was supported by The Leukemia and Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/deluge/c8641f38-69d9-13d3-34c8-663ded82ead0.mp3
Practical Tips for Managing Your Finances and Insurance 2
11/28/07 This program featured Beth Darnley, chief program officer, Patient Advocate Foundation, Newport News, Virginia and Anita Welborn, LMSW, director, Information Resource Center (IRC), The Leukemia & Lymphoma Society, White Plains, NY. This program was sponsored by The Leukemia & Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/download/ad858520-9141-1dc0-83f9-d88f41c26ae8.mp3
Advocating For Your Child's Learning Needs
2/13/08 Advocating For Your Child's Learning Needs: Through Treatment and Beyond This program featured Daniel Armstrong, PhD, professor & associate chair, Department of Pediatrics, director, Mailman Center for Child Development, associate chief of staff, Holtz Children's Hospital at the University of Miami, Jackson Memorial Medical Center, director, University of Miami Sickle Cell Center, Miami, Florida. This program was part of our Focus on Childhood Cancers Educational Series and was sponsored by The Leukemia and Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/deluge/ceab5a99-d0bd-9b91-fe70-bcf68ea5001c.mp3
Practical Tips for Managing Your Finances and Insurance 1
11/28/07 Cancer Survivorship: Practical Tips for Managing Your Financial and Insurance Issues - Part 1 of 2 This program featured Beth Darnley, chief program officer, Patient Advocate Foundation, Newport News, Virginia and Anita Welborn, LMSW, director, Information Resource Center (IRC), The Leukemia & Lymphoma Society, White Plains, NY. This program was sponsored by The Leukemia & Lymphoma Society. Alternate link to the audio: http://lls.hipcast.com/download/2b62f7e8-7e73-ab61-88c1-70c8794e4aca.mp3
Spotlight on New Discoveries in NHL Part 2
12/12/2007 Update from the American Society of Hematoloty (ASH) Annual Meeting This program featured Wyndham Wilson, M.D., Ph.D, senior investigator, head, Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD. Alternate link to the audio: http://lls.hipcast.com/deluge/c191974d-8461-640b-c8af-0f769e8a66da.mp3

Hematological Cancer News Articles Provided by Cancer Compass
CancerCompass is dedicated to provided you with the most up to date cancer information and news. Visit our website to find all our articles on Hematological Cancer News

Physical Activity Associated With Healthier Aging
Physical activity appears to be associated with a reduced risk or slower progression of several age-related conditions as well as improvements in overall health in older age, according to a commentary and four articles published in the January 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
New Osteonecrosis Study Findings Have Been Published By Scientists At University Of Bari
Osteonecrosis of the jaws (ONJ) is a well known side effect of bisphosphonate therapies in patients with multiple myeloma or other malignancies. Its real incidence is still undetermined, and only few cases of ONJ in patients taking bisphosphonates for non- oncologic diseases have been reported, scientists writing in the Journal of Rheumatology report.
IsoRay Announces It Has Provided Seeds To Canada For Research Initiatives To Expand The Use Of Cesium-131 For New Cancer Applications
IsoRay, Inc. announced that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).
Wrap Your Hands Around A Bowl Of One Of These Hearty Soups
Almost nothing tastes better on a cold, gray day than a piping bowl of soup. And almost nothing more easily feeds a crowd. So we asked readers to send us their favorite soup and stew recipes - - the ones they simmer on the stove when there's a chill in the air, or when they find themselves with a house full of guests.
About 40 Percent Of Cancers Can Be Prevented With Lifestyle Changes, Vaccines
About 40 percent of cancers could be prevented if people stopped smoking and overeating, limited their alcohol, exercised regularly and got vaccines targeting cancer-causing infections, experts say.
Berry, Berry Healthy?: Super Fruits' Nutritional Benefits Remain Unclear
They could be called super berries. Borrowing the super label from other fruits that are high in antioxidants, the berries with both foreign- sounding and familiar names are stars of the natural-foods and alternative-medicine worlds: acai, aronia, goji, sambucus, even coffeeberry.
Fennel And Pork Add Dramatic Touches To Savory Squash Stew
You can't judge a book by its cover. But vegetables are another story: The more vibrant the flesh, the more nutrients it contains. For instance, orange-hued winter squash are naturally chock-full of beta-carotene, fiber, magnesium and potassium.
New Vitamin D Recommendation Expected
Some patients love their vitamins, spending hundreds to thousands of dollars annually. At times, they will even forgo proven medical therapy. As more Americans go without health insurance coverage while others face higher office visits and copays, increasing numbers of patients are seeking alternative natural therapies instead of medical care.
NIH To Track Patients' Radiation Exposure
Concerned that Americans may be accumulating too much lifetime radiation exposure from medical tests, doctors at the National Institutes of Health will begin recording how much radiation patients receive from CT scans and other procedures in their electronic medical records.
On Nutrition: Good, Bad Body Fat
How do you come up with the topics for your column? someone asked me last week. Sometimes it's just what is on my heart and mind, I answered. Like today; one hour before deadline and I am still thinking about fat. Not a particularly nice name in our culture. We blame it for much of our misery...tight clothes, clogged arteries and extra pounds.
Blood Test Could Improve Graft-Versus-Host Disease Treatment
University of Michigan researchers have identified the first biomarker of graft-versus- host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants. The biomarker also makes it possible to predict who is at greatest risk of dying of graft-versus-host disease, or GVHD.
New Myeloma Study Findings Have Been Reported By Scientists At National Hospital Organization
According to a study from Okayama, Japan, The efficacy and safety of high-dose chemotherapy with tandem autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in a multicenter clinical study of patients with advanced multiple myeloma. Eligible patients (n = 40) were consecutively enrolled in the phase I/II study and received 2-4 cycles of vincristine-adriamycin-dexamethasone regimen.
Med Students Say Conventional Medicine Would Benefit By Integrating Alternative Therapies
In the largest national survey of its kind, researchers from UCLA and UC San Diego measured medical students' attitudes and beliefs about complementary and alternative medicine (CAM) and found that three-quarters of them felt conventional Western medicine would benefit by integrating more CAM therapies and ideas.
Soup: The Ultimate Comfort Food
My slow cooker is used for one purpose: Cooking onions. And I cook those onions for one reason: So we can have French onion soup on a moment's notice.
Stricter Rules Urged On Toxic Chemicals: Report Links Exposure To Chronic Illnesses, Cancers
Americans are exposed to thousands of chemicals that are potentially harmful to their health, according to a broad coalition of labor, health, and environmental organizations calling for tougher federal toxics regulation.
New Myeloma Research Reported From Mayo Clinic
Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase 11 trial of the immunotherapeutic, APC8020 (Mylovenge), given after ASCT for MM, investigators in the United States report.
CytRx To Conduct Phase 2 Clinical Trial With Bafetinib In B-Cell Chronic Lymphocytic Leukemia
CytRx Corporation, a biopharmaceutical company specializing in oncology, announced plans to initiate a Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib (formerly known as INNO-406) in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).
Research from Washington University In The Area Of Plasma Cell Leukemia Published
Primary plasma cell leukemia (PCL) is a rare plasma cell disorder, and current knowledge regarding survival in this disease is limited to small series of patients. Although there has been significant improvement in the survival of patients with multiple myeloma (MM) over the past few decades, it is not known whether there has been a similar trend for PCL, investigators in the United States report.
Innovative Technique Allows Male Cancer Survivors Sterile From Treatment To Father Children
Men who were previously deemed sterile due to aggressive cancer treatments may still be able to biologically father children according to a new study published in the journal, Bone Marrow Transplantation.
Sugary Temptation: What Are The Best -- And Sweetest -- Sugar Alternatives For Your Body?
The human body needs sugar. But before those with a penchant for sweets get too excited, the body can get all the sugar it needs from a balanced diet of fruits, vegetables, whole grains and proteins. Not a single cupcake is required.







For more news about Non-Hodgkin Lymphoma go to MedWorm: Non-Hodgkin Lymphoma. This MedWorm page is more technical and is most likely more useful to oncologists. But for patients who want to know about cutting edge treatments and research for NHL, this MedWorm page will also be useful.

Powered by FirstRSS Plugin